TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML)
| Autor: | N Boissel, Lea Payen-Gay, Hussein Mortada, Pascale Flandrin-Gresta, Catherine Koering, Eric Wattel, Delphine Maucort-Boulch, Didier Auboeuf, Sandrine Hayette, Emeline Cros, Mohamed El-Hamri, Antony Ceraulo, Aminetou Mint Mohamed, Olivier Nibourel, Denis Guyotat, Isabelle Tigaud, Claude Preudhomme, Françoise Solly, Mauricette Michallet, Meyling Cheok, Lydia Campos, Franck-Emmanuel Nicolini, Franck Mortreux, Xavier Thomas, Christiane Pinatel, Charles Dumontet, Marie Balsat |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Prognostic factor Acute myelogenous leukemia (AML) business.industry Complete remission Cytogenetics Hematology medicine.disease 03 medical and health sciences Exon NPM1 Mutation 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Immunology Cohort Medicine Cumulative incidence business |
| Zdroj: | Leukemia Research. 56:21-28 |
| ISSN: | 0145-2126 |
| Popis: | In AML, approximately one-third of expressed genes are abnormally spliced, including aberrant TET2 exon 2 expression. In a discovery cohort (n=99), TET2 exon 2 skipping (TET2E2S) was found positively associated with a significant reduction in the cumulative incidence of relapse (CIR). Age, cytogenetics, and TET2E2S were independent prognostic factors for disease-free survival (DFS), and favorable effects on outcomes predominated in cytogenetic normal (CN)-AML and younger patients. Using the same cutoff in a validation cohort of 86 CN-AML patients, TET2E2Shigh patients were found to be younger than TET2low patients without a difference in the rate of complete remission. However, TET2E2Shigh patients exhibited a significantly lower CIR (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect